>
This is the future we shall bring into being
Elon Musk's Vision For The Future Looks Like A Movie
Phosphorus Munitions Fired by Israel Burn Groves, Orchards in Southern Lebanon
Iran's IRGC Warns It Will Expand 'Geography of the War' If the US Attacks Again
BEYOND THE MOON: NASA plans a nuclear-powered fleet to push DEEPER into space
Big Oil Backs Mazama's $135 Million Bet On Superhot Geothermal
Quantum compass takes flight on Northrop's Lumberjack drone
Terrifying AI Behavior Even Its Creators Couldn't Explain
WW3 Near-Miss? AI Hallucinated Nuclear Weapons Components Aboard Chinese Vessel Bound For Iran
Stripe Is Building the Toll Road for the Machine Economy
Toyota Dakar hopeful swaps twin-turbo V6 for hydrogen fuel cells
4-min turbo-inflatable cubic camp castle is now available in the USA
Researchers Used Claude To Hack OpenAI Employee Accounts
Chinese Scientists Develop New Oil Refining Method That Cuts Energy Use by 90%

The study's lead researcher, Dr. Robert Naviaux of the San Diego School of Medicine is an internationally known expert in human genetics, inborn errors of metabolism, metabolomics, and mitochondrial medicine. He is the discoverer of the cause of Alpers syndrome — the oldest Mendelian form of mitochondrial disease — and the developer of the first DNA test to diagnose it. Naviaux is, by far, one of the most qualified people in the world to conduct this study.
During his research, Naviaux noted the transformative results of the drug suramin which was first developed in 1916 and used as an anti-parasitic drug for treating African sleeping sickness and river blindness. After giving a single dose of suramin to boys with autism, between the ages of five and 14, Naviaux recorded something incredible — their symptoms were significantly alleviated.
"After the single dose, it was almost like a roadblock had been released," he said. "If the future studies show that there's continued health benefits, this could be a game-changer for families with autism."